Strategic Site Selection Improves Minority Representation in Stent Trials

Bridging the Demographic Gap in Cardiovascular Device Validation

The clinical utility of cardiovascular interventions depends on transparent reporting and external validity, which is the extent to which results apply to real-world patients [1, 2]. Meta-analytic data involving 135,000 patients show that antiplatelet therapy reduces serious vascular events by approximately 25%, yet the benefit-to-risk ratio remains highly dependent on individual comorbidities [3]. For instance, in patients with both atrial fibrillation and stable coronary artery disease, combining anticoagulants with antiplatelet therapy increases the risk of major bleeding (Hazard Ratio 1.62; 95% CI, 1.40 to 1.86) without significantly reducing major adverse cardiovascular events [4]. Because the prevalence of these complex cases is rising, clinical guidelines stress that trial participants must reflect the intended-use population to ensure generalizability [5, 6]. A recent study evaluates how research site selection influences the demographic makeup of coronary stent trials, offering a strategy to better align clinical research with the diverse patients seen in daily practice.

Quantifying the Representation Gap in Pivotal Stent Studies

To evaluate the demographic landscape of cardiovascular research, investigators pooled data from 8,859 U.S. participants enrolled in 9 pivotal coronary stent premarket approval studies between 2003 and 2018. These premarket approval trials evaluate Class III cardiovascular devices, representing the highest risk category of medical hardware requiring the most stringent regulatory oversight, and were conducted across 196 research sites. The analysis focused on how closely these trials aligned with the intended-use population, which is the real-world patient group for whom the device is clinically indicated. The authors observed that these studies often fail to fully represent this population due to low enrollment of racial and ethnic minority subjects and women. The study utilized the participant-to-prevalence ratio (a metric comparing the proportion of a demographic group in a clinical trial to their proportion in the general population with the disease) to quantify these disparities. The findings revealed that minority participants comprised only 12% of the total study population, resulting in a participant-to-prevalence ratio of 0.48. This indicates that minority groups were represented at less than half the rate of their actual disease prevalence. Because of this marked underrepresentation of minority participants, coronary stent premarket approval studies do not fully reflect the intended-use population. A similar trend was identified regarding sex, though the gap was less pronounced. Women comprised 30% of the total study population, yielding a participant-to-prevalence ratio of 0.77. While this represents a modest underrepresentation of women compared to racial and ethnic minorities, it reinforces the conclusion that these pivotal trials do not fully reflect the patients treated in daily practice. For the practicing cardiologist, these data highlight a significant gap between the demographics of patients in clinical trials and the diverse populations receiving stents in the catheterization lab, raising concerns about whether device efficacy and safety profiles translate equally across all demographic groups.

Predictors of Minority Enrollment and the Impact of Geography

To understand why certain clinical trials achieve higher diversity than others, the researchers evaluated a comprehensive set of site-level variables across the 196 participating locations. The site characteristics analyzed included the U.S. region, surrounding county demographics, teaching status, and Veterans Administration affiliation. Furthermore, the authors examined the number of acute hospital beds, the total trial volume at each location, and the involvement of a female principal investigator (the lead physician responsible for the conduct and supervision of the trial at a specific site). The analysis revealed that minority enrollment varied markedly across sites, suggesting that the specific selection of research centers is a primary driver of demographic representation in cardiovascular device studies. The researchers utilized multivariable regression, a statistical method used to quantify how multiple independent variables simultaneously influence a single outcome, to identify the strongest drivers of recruitment. The multivariable regression model for minority enrollment predictors had an R-squared value of 0.50 (P < 0.001), indicating that the model explained 50% of the variance in minority participation. Specifically, minority enrollment was predicted by West and South regions, county minority population, population density, and per-capita income. These data suggest that geographic location and the socioeconomic environment of the research site are highly predictive of a trial's ability to recruit a diverse patient population, whereas other factors like hospital size or teaching status played a less decisive role. For clinicians relying on trial data, this underscores that where a trial is conducted heavily dictates who is enrolled, directly impacting the external validity of the results.

Modeling Site Reallocation to Normalize Trial Demographics

To determine if the demographic gap in clinical trials is addressable through administrative changes, the researchers performed a modeling analysis to simulate the effects of strategic site selection. This process involved estimating the impact of reallocating patient enrollment from sites with low minority recruitment to those with historically high minority enrollment. Because the study found that minority enrollment is influenced by site characteristics such as geographic region and county demographics, the authors concluded that targeted site selection could improve minority representation in future premarket approval studies. This suggests that the current underrepresentation is not an inevitable feature of clinical research but rather a consequence of where trial resources are currently distributed. The modeling results indicated that such a shift in site selection could significantly improve the participant-to-prevalence ratio. The researchers estimated that reallocating enrollment from low to high minority-enrolling sites could normalize Black and Hispanic representation to participant-to-prevalence ratios of 0.80 or higher. A ratio of 1.00 indicates perfect alignment with the disease population, while a ratio of 0.80 is often cited as a benchmark for adequate representation. Crucially, the analysis demonstrated that reallocating enrollment to high minority-enrolling sites would not compromise the representation of non-Hispanic Whites, who maintained a participant-to-prevalence ratio of 1.00 in the simulation. These findings provide a data-driven roadmap for trial sponsors to design studies that more accurately reflect the diversity of patients who will ultimately receive these cardiovascular devices, ensuring that physicians have robust, applicable data for all their patients.

The Persistent Challenge of Female Participant Recruitment

In contrast to the significant geographic and site-specific variations observed in minority recruitment, female enrollment showed less variation across sites in the nine pivotal coronary stent studies analyzed. While site selection proved to be a viable lever for increasing racial and ethnic diversity, the same factors did not apply to women. The researchers utilized a multivariable regression model to identify predictors of female participation. This model yielded an R-squared value of 0.095 (P < 0.001), indicating that site characteristics and investigator demographics explained less than 10% of the variance in female enrollment. Among the variables tested, female enrollment was poorly predicted by research site characteristics and site principal investigator gender, with the exception of non-Veterans Administration status. The study also examined whether the gender of the site leadership influenced participant demographics, but the data were constrained by a significant gender imbalance among researchers. Fewer than 6% of principal investigators in the studies were female, a disparity that limited the ability to correlate investigator gender with female participant enrollment patterns. Because female participation remained consistently low regardless of the facility type or the geographic location, the authors concluded that the barriers to female participation are likely systemic or related to patient-level factors rather than geographic or institutional ones. Consequently, while strategic site selection may normalize minority representation, improving female enrollment requires alternative strategies beyond administrative site reallocation. For the practicing clinician, these findings suggest that ensuring cardiovascular trials reflect the intended-use population of women will necessitate targeted recruitment efforts that address specific barriers to entry, ultimately providing more reliable safety and efficacy data for female patients.

References

1. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010. doi:10.1136/bmj.c869

2. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology. 2010. doi:10.1016/j.jclinepi.2010.03.004

3. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002. doi:10.1136/bmj.324.7329.71

4. Ullah W, Sattar Y, Shaukat M, Fischman DL. Safety and efficacy of anticoagulant monotherapy in atrial fibrillation and stable coronary artery disease: A systematic review and meta-analysis.. European journal of internal medicine. 2020. doi:10.1016/j.ejim.2020.06.035

5. Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021. doi:10.1093/eurheartj/ehab484

6. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023. doi:10.1161/cir.0000000000001193